Abstract: Provided is a pharmaceutical agent capable of efficiently improving blood circulation in a region where a circulatory disorder occurs and fully preventing or improving tissue damage as a preventive or therapeutic agent for circulatory disorders in general. As a result of the study of pharmacological effects of a compound in which a porphyrin metal complex is clathrated in albumin, it was found that the compound efficiently improves decreases in blood flow in circulatory disorders and fully prevents or improves tissue damage, thus the invention was achieved. That is, the invention is directed to an agent for improving a circulatory disorder including a compound in which a porphyrin metal complex is clathrated in albumin.

Abstract: There is provided a radiosensitizer containing an iron compound, more specifically, a radiosensitizer containing an iron compound selected from an inorganoiron compound, such as iron chloride, iron oxide, iron hydroxide, and iron sulfate; and an organoiron compound, such as saccharated ferric oxide, iron citrate, iron gluconate, chondroitin sulfate/iron colloid, cideferron, ferrotrenine, iron fumarate, iron pyrophosphate, a porphyrin-iron complex, and an albumin incorporating porphyrin-iron complex.

Abstract: A pharmaceutical composition excellent for treatment or prevention of a glaucoma or an ocular hypertension, which inhibits the development of drug resistance, and which can be administered for a longer period of time is provided.

Abstract: Ophthalmic compositions having negligible side effects on the heart can be obtained by using as the active ingredient an adrenergic &bgr; receptor agonist having a high selectivity toward adrenergic &bgr;2 receptor. These compositions are usable as preventives or therapeutics for xerophthalmic disorder and keratoconjunctival disorder.

Abstract: Ophthalmic compositions having negligible side effects on the heart can be obtained by using as the active ingredient an adrenergic &bgr; receptor agonist having a high selectivity toward adrenergic &bgr;2 receptor. These compositions are usable as preventives or therapeutics for xerophthalmic disorder and keratoconjunctival disorder.

Abstract: A benzoxazepine derivative having the general formula (I) and its salts and medicaments containing the same as effective ingredients: wherein, n is an integer of 2 to 5, R1 indicates a hydrogen atom, halogen atom, C1 to C4 lower alkyl group, C1 to C4 lower alkoxyalkyl group, C1 to C4 halogenoalkyl group, cyano group, or ester group, R2 indicates a hydrogen atom, halogen atom, C1 to C4 lower alkyl group, C1 to C4 lower alkoxy group, or hydroxy group, a dotted line indicates the presence or absence of a binding bond, W indicates C, CH, or CH2 or a nitrogen atom, provided that, when W is a nitrogen atom, Z is bonded to W and the dotted line indicates the absence of a bond, and Z indicates an unsubstituted or substituted aromatic hydrocarbon ring group or an unsubstituted or substituted heterocyclic group).